Blackston Financial Advisory Group LLC Buys Shares of 4,160 Bristol-Myers Squibb (NYSE:BMY)

Blackston Financial Advisory Group LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,160 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Several other institutional investors have also bought and sold shares of BMY. Ballentine Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 9.5% in the 3rd quarter. Ballentine Partners LLC now owns 39,045 shares of the biopharmaceutical company’s stock worth $2,020,000 after acquiring an additional 3,399 shares during the period. Moody Lynn & Lieberson LLC lifted its position in Bristol-Myers Squibb by 176.6% in the third quarter. Moody Lynn & Lieberson LLC now owns 23,029 shares of the biopharmaceutical company’s stock worth $1,192,000 after purchasing an additional 14,704 shares during the period. DT Investment Partners LLC boosted its stake in Bristol-Myers Squibb by 1.7% during the 3rd quarter. DT Investment Partners LLC now owns 20,831 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 349 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Bristol-Myers Squibb by 12.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 64,191 shares of the biopharmaceutical company’s stock valued at $3,321,000 after purchasing an additional 7,245 shares during the period. Finally, Pinnacle West Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 2.3% in the 3rd quarter. Pinnacle West Asset Management Inc. now owns 13,550 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 300 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. Finally, Barclays upped their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $53.31.

Bristol-Myers Squibb Trading Down 1.0 %

Shares of NYSE:BMY opened at $52.40 on Friday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $55.29. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The firm has a market capitalization of $106.22 billion, a P/E ratio of -17.07, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The firm has a fifty day moving average of $50.63 and a two-hundred day moving average of $46.39.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.75 earnings per share. On average, equities analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.58%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.